Ranibizumab port delivery system: a clinical perspective. Issue 1 (26th September 2022)

• Record Type: Journal Article
• Authors: Eichenbaum, David A; Ahmed, Abrahim; Hiya, Farhan
• Is Part Of: BMJ open ophthalmology. Volume 7:Issue 1(2022)
• Publication Date: 2022-09-26
• Subjects: Retina -- Angiogenesis -- Macula -- Treatment Surgery -- Neovascularisation -- Degeneration; Ophthalmology -- Periodicals; 617.7005
• DOI: 10.1136/bmjophth-2022-001104
• Languages: English
• ISSNs: 2397-3269

Abstract

Abstract : Age-related macular degeneration (AMD) represents a leading cause of blindness worldwide. Neovascular AMD (nAMD) is a subtype of AMD most frequently treated with intravitreal anti-vascular endothelial growth factor (aVEGF) injections, which has allowed for patients to maintain vision that would have otherwise been lost. However, the need for frequent intravitreal injections for optimal results poses a risk for undertreatment in nAMD patients due to the high treatment burden associated with current aVEGF therapy. Many novel agents and pathways are being explored and targeted for less burdensome treatment options, one of which is the ranibizumab port delivery system (PDS). The PDS is a surgically implanted, refillable device that allows for the sustained release of ranibizumab, a widely used aVEGF agent, into the vitreous cavity. Positive results non-inferior to monthly ranibizumab injections in both phase II and phase III clinical trials allowed for FDA approval of the device with refill intervals of 6 months, which represents the longest approved treatment interval to date for nAMD therapy. This article reviews the need for a durable nAMD treatment option in real-world practice, the clinical trial and extension study data for the PDS, the risk of adverse events and safety profile of the PDS and the potential clinical role of the PDS in answering the real-world needs of nAMD treatment. In addition, other pipeline sustained-treatment modalities are discussed in the context of ongoing clinical trials.